MPL 免疫组化表达作为鉴别特发性血小板增多症和原发性骨髓纤维化的新型标志物。
MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis.
机构信息
Department of Pathology, Universidade Federal de São Paulo, São Paulo, Brazil.
出版信息
Leuk Res. 2012 Jan;36(1):93-7. doi: 10.1016/j.leukres.2011.06.024. Epub 2011 Jul 12.
To evaluate the grading of fibrosis and immunohistochemical expression of MPL in bone marrow biopsies of ET and PMF. Fibrosis in bone marrow biopsies (BMBs) was evaluated according to the European Consensus for grading of fibrosis, according to reticulin proliferation. Immunohistochemical analysis was performed in samples from 18 ET and 38 PMF patients: 19 were classified as pre-fibrotic and 19 were classified as fibrotic according to the World Health Organization (WHO) criteria, by means of the MPL antibody. Six bone marrow donors' biopsies were used as controls. Average reticulin (p<0.003) and MPL (p<0.008) values differed significantly between the ET group and the pre-fibrotic stage PMF group. The MPL immunohistochemical expression may represent a new marker for differential diagnosis between ET and pre-fibrotic stage PMF.
评估 ET 和 PMF 患者骨髓活检中纤维化的分级和 MPL 的免疫组化表达。根据网状纤维增生情况，按照欧洲纤维化分级共识对骨髓活检（BMB）中的纤维化进行评估。对 18 例 ET 和 38 例 PMF 患者的样本进行了免疫组化分析：根据世界卫生组织（WHO）标准，19 例患者被归类为前纤维化，19 例患者被归类为纤维化，采用 MPL 抗体。6 例骨髓供体活检作为对照。ET 组与前纤维化期 PMF 组之间平均网状纤维（p<0.003）和 MPL（p<0.008）值差异有统计学意义。MPL 免疫组化表达可能是 ET 和前纤维化期 PMF 之间鉴别诊断的一个新标志物。
Zotero 插件